Dr Alberto Lledó has joined Canbex Therapeutics as Chief Medical Officer (CMO).
Dr Lledó is currently a Senior Consultant Neurologist at Clínica Creu Blanca, Barcelona, Spain, although his pharma experience includes 16 years at Eli Lilly.
During his time at Lilly he was Global Senior Medical Advisor and CNS Clinical Research Physician for Europe, and helped coordinate Phase II clinical trials for the company's neurology pipeline.
As Chief Medical Officer at Canbex he will lead preparations for proof of concept trials for VSN16R, the company's orally active small molecule for the treatment of spasticity in multiple sclerosis.
'I am delighted to be joining Canbex at such an important time in the development of VSN16R,' said Dr Lledó. 'I share with Canbex the belief that VSN16R has the potential to set a new standard in the treatment of spasticity, and to improve the lives of multiple sclerosis patients worldwide.'
Dr Lledó will take over as CMO from Dr Miroslav Ravic, who is guiding the company through completion of its Phase I study.
Investors in Canbex include MS Ventures, the corporate venture arm of Merck KGaA; the Wellcome Trust; Fast Forward, the drug development arm of the US National Multiple Sclerosis Society; University College London; and Esperante Ventures.